

To: **Bhagirathi Neotia Women & Child Care Centre(A Unit Of Park Hospital)**  
Premises No.27-0327,  
Street No. 327, Action Area 1D, New Town  
Kolkata - 700156  
Contact:  
**Report Of: Mrs. NUSRAT JAHAN**  
Pt. Contact: 8918959509



Sample ID 2390011512  
Patient ID 190235768  
Hospital ID UID210000077947  
Received on 13/09/2023 11:54  
Registered on 13/09/2023 13:02  
Reported on -  
Referred by -  
Sonography by **Dr. JASMINE REZA**  
**Dr. Moon Kanjilal**

Understand Your Report In Detail



Scan QR code

**EVICOSCREEN - EVIDENCE BASED COMPREHENSIVE PRENATAL SCREENING REPORT**

**Patient Name: Mrs. NUSRAT JAHAN**

**Patient DOB: 05/02/2002**

EVICOScreen™ is an evidence based prenatal screening program curated by Lilac Insights in accordance with the Fetal Medicine Foundation (UK) guidelines for First Trimester Screening to determine the probability of most common chromosomal aneuploidies in a pregnancy. It utilizes:

- Hormonal values from the pregnancy measured on Fetal Medicine foundation (UK) accredited analyzers and reagents
- Robust indigenous medians from over 7 lac+ pregnancies for different gestation ages
- Risk calculations from evidence based algorithms validated through large international studies

**UKNEQAS: United Kingdom National External Quality Assessment Service**

**RIQAS: Randox International Quality Assessment Scheme**



The Risk Assessment Performed Using CE-marked Antenatal Risk Evaluation Software Certified by the British Standards Institute (BSI)- ISO 13485:2016

**RISK ASSESSMENT**

Condition	Ratio	Risk Level	Visual Scale
T21 (Down syndrome)	1: 100000	Low Risk	LOW (Green)   HIGH (Red)
T18 (Edwards' syndrome)	1: 100000	Low Risk	LOW (Green)   HIGH (Red)
Neural tube/ Abdominal wall defect	-	High Risk	LOW (Green)   HIGH (Red)

**MULTIPLE OF MEDIAN (MoM)**

Free β-hCG	4.86	Red
AFP	2.51	Red
uE3	1.50	Green
Inhibin-A	3.68	Red

**INTERPRETATION**

The Quadruple Screening for the given sample is found **SCREEN POSITIVE** for Neural Tube/Abdominal wall Defect.

**SUGGESTIONS AND OTHER FINDINGS**

- Detailed anomaly scan to assess for fetal abnormalities especially that of the spine, anterior abdominal wall and kidneys.
  - In the absence of any fetal anomalies, suggest serial growth scans from 26 weeks onwards.
- In view of free bHCG MoMs observed in the mother, kindly consider correlation with fetal growth and well being scan at 28 - 30 weeks.  
In view of Inhibin-A MoMs observed in the mother, please correlate clinically with ultrasound findings.



*Pradip Kadam*

Verified by  
**Mr. Pradip Kadam**  
Incharge Biochemistry

*Suresh Bhanushali*

Verified by  
**Dr. Suresh Bhanushali**  
MD (Path), Consultant Pathologist

Patient name: Mrs. NUSRAT JAHAN

Sample ID: 2390011512

Sample Type: Serum

Risk assessment: Algorithm validated by SURUSS 2003, N.J Wald

Method: Chemiluminescence

### PREGNANCY DETAILS

No. of fetuses : 1      EDD : 19/02/2024      Age at Term : 22.0 Years  
 GA is Based on : CRL 22.7mm at 17/07/2023      LMP Date :      LMP Certainty : Unknown  
 Smoking : None      Parity :      Height :      Weight : 60.96 Kg  
 Ethnicity: Asian      FHR :

#### Previous pregnancy history

Down syndrome       Edwards' syndrome  
 Patau syndrome       NTD syndrome

#### Pre-eclampsia history

PE in previous pregnancy  
 Pat. mother had PE

#### Other findings

Insulin dependent diabetes  
 Chronic hypertension

EDD: Estimated Due Date | GA: Gestation Age | LMP: Last Menstrual Period | FHR: Fetal Heart Rate | NTD: Neural Tube Defect | PE: Pre-eclampsia | DOB: Date of Birth

### SPECIMEN DETAILS

Sample ID	: 2390011512	CRL	: 22.7 mm	Test Name	Conc.	Unit	Corr. Mom
Collection Date	: 11/09/2023	CRL2	:	Free-β-hCG	63.26	ng/mL	4.86
Scan Date	: 17/07/2023	BPD	:	AFP	100.70	ng/mL	2.51
GA at Coll Date	: 17 Weeks 0 Days	BPD2	:	uE3	06.01	nmol/L	1.50
GA at Scan Date	: 9 Weeks 0 Days	HC	:	Inhibin A	702.40	pg/mL	3.68
Received on	: 13/09/2023	HC2	:				

GA: Gestation Age | CRL: Crown Rump Length | BPD: Bi-parietal Diameter | HC: Head Circumference | free-β-hCG: free-Beta Human Chorionic Gonadotropin  
 NT: Nuchal Translucency | PAPP-A: Pregnancy-associated Plasma Protein-A

### RISKS

<b>Disorder: Down Syndrome</b>	<b>Result:</b>	<b>Low Risk</b> ●
Final risk: 1:100000      Age risk: 1:1500		
Cutoff 1:250      Risk type Risk At Term		
<b>Disorder: Edwards' Syndrome</b>	<b>Result:</b>	<b>Low Risk</b> ●
Final risk: 1:100000      Age risk: 1:8900		
Cutoff 1:100      Risk type Risk At Term		
<b>Neural tube / Abdominal wall defect</b>	<b>Result:</b>	<b>High Risk</b> ●
Final risk: -      Age risk:		
Cutoff 2.5      Risk type Risk at Term		

Patient name : Mrs. NUSRAT JAHAN

Sample ID : 2390011512

## PRENATAL SCREENING BACKGROUND

Every pregnant woman carries a certain degree of risk that her fetus/baby may have certain chromosomal defect/ abnormalities. Diagnosis of these fetal chromosomal abnormalities requires confirmatory testing through analysis of amniocytes or Chorionic Villous Samples (CVS). However, amniocentesis and CVS procedures carry some degree of risk for miscarriage or other pregnancy complications (Tabor and Alfirevic, 2010). Therefore in routine practice, prenatal screening tests are offered to a pregnant woman to provide her a personalised risk for the most common chromosomal abnormalities (T21-Down syndrome, T18- Edwards' syndrome, T13- Patau syndrome) using her peripheral blood sample. Based on this risk assessment, if the risk is high or intermediate, you can take informed decision of opting for invasive procedure such as amniocentesis or CVS followed by confirmatory diagnostic test(s), as per discussion with your clinician.

### PRENATAL SCREENING TESTS ARE NOT CONFIRMATORY TESTS. THEY ARE LIKELIHOOD ASSESSMENT TESTS.

You may get your prenatal screening result as either of the following:-

#### High Risk

**High Risk or Screen Positive Result:** A High Risk Result does not mean that the pregnancy is affected with the condition. It means that the likelihood of the pregnancy having a condition is higher than the cut-off (Most commonly used cut-off is 1:250 and this represents the risk of pregnancy loss from confirmatory testing through CVS or amniocentesis).

#### Low Risk

**Low Risk or Screen Negative Result:** A Low Risk result does not mean that the pregnancy is not affected with a condition. It means that the likelihood of the pregnancy having a condition is lower than the cut-off.

## SIGNIFICANCE OF MULTIPLE OF MEDIANS (MoMs)

Prenatal Screening determines the likelihood of the pregnancy being affected with certain conditions by analysing levels of certain hormones. These hormones are Feto placental products (released by Fetus or placenta). Their levels not only indicate propensity of the fetus being affected with certain chromosomal conditions, they also provide indication of placental insufficiency that can potentially lead to pregnancy complications like Pre-Eclampsia or Intra-Uterine Growth Restriction. It is therefore important to take cognisance of the Reported MoMs alongside the Risk results.

For more information, visit our website at: [www.lilacinsights.com/faq-pns](http://www.lilacinsights.com/faq-pns)

## DISCLAIMERS

### Limitations of the Test:

As prenatal screening tests are not confirmatory diagnostic tests, the possibility of false positive or false negative results can not be denied. The results issued for this test does not eliminate the possibility that this pregnancy may be associated with other chromosomal or sub- chromosomal abnormalities, birth defects and other complications.

Nuchal Translucency is the most prominent marker in screening for Trisomy 13, 18, 21 in the first trimester and should be measured in accordance with the Fetal Medicine Foundation (UK) guidelines. Nuchal Translucency or Crown Rump Length measurement, if not performed as per FMF (UK) imaging guidelines may lead to erroneous risk assessments and Lilac Insights bears no responsibility for errors arising due to sonography measurements not performed as per these criteria defined by international bodies such as FMF (UK), ISUOG.

It is assumed that the details provided along with the sample are correct. The manner in which this information is used to guide patient care is the responsibility of the healthcare provider, including advising for the need for genetic counselling or additional diagnostic testing like amniocentesis or Chorionic Villus Sampling. Any diagnostic test should be interpreted in the context of all available clinical findings. As with any medical test, there is always a chance of failure or error in sample analysis though extensive measures are taken to avoid these errors.

### Note:

- Quality of the Down's Syndrome & ONTD screening program (Biochemical values, MoMs and Risk assessments) monitored by UKNEQAS on an ongoing basis.
- This interpretation assumes that patient and specimen details are accurate and correct.
- Lilac Insights does not bear responsibility for the Ultra sound measurements.
- This is a risk estimation test and not a diagnostic test . An increased risk result does not mean that the fetus is affected and a low risk result does not mean that the fetus is unaffected. Reported risks should be correlated and adjusted according to the absence/presence of sonographic markers observed in the anomaly/malformation scan.
- The above risk has been calculated based on Biochemistry values alone.
- It must be clearly understood that the results represent risk and not diagnostic outcomes. Increased risk does not mean that the baby is affected and further tests must be performed before a firm diagnosis can be made. A low risk result does not exclude the possibility of Down's Syndrome or other abnormalities, as the risk assessment does not detect all affected pregnancies.
- Each sample received at Lilac Insights' processing centre is handled with the utmost sensitivity and care. All samples received on Sundays and National holidays are stored as per specific guidelines for the respective specimens and processed on the next day.

END OF REPORT

Page 3 of 3



UK NEQAS  
International Quality Expertise  
Lab Reg. No. 90968